Opentrons announces $40m Series E funding round
Opentrons Labworks has announced a $40 million Series E financing led by healthcare investor Avego, with additional investment from BroadOak Capital Partners.
Opentrons says it will use the capital to scale its robotics, software, and data infrastructure tools.
While AI is transforming how science is conducted, Opentrons says the physical lab has become a bottleneck. Scientists can use frontier models to generate hypotheses and design experiments far faster than laboratories can test them.
Opentrons hopes to close that gap with its Opentrons Flex platform, which includes robots and AI systems that enable experiments to be designed, run, and improved in a continuous loop.
The company has deployed over 11,000 robots to laboratories in over 80 countries, including at 90% of the top 20 global pharmaceutical companies.
“Millions of scientists spend much of their day on manual work a robot can do. Giving that time back to discovery is the biggest opportunity in science,” said James Atwood, CEO of Opentrons. “We made lab automation accessible for any lab, and our systems are built for AI to run experiments directly. That is why autonomous science is standardising on Opentrons.”
The Series E will fund Opentrons’ next phase of growth in autonomous science, where its AI and robotics systems work together to design, execute and learn from experiments required to achieve its customers’ scientific goals.
The company has revealed plans to invest in AI-driven experimental execution, extend its automation capabilities, and expand into new markets and geographies.
“Every AI-driven discovery still has to be tested in a real lab,” said James Flexner, Managing Partner at Avego. “Drug developers and AI companies alike are moving experimental work forward toward automated workflows that generate usable data. We see a significant opportunity for autonomous science to converge around Opentrons’ platform.”
